GLTO — Galecto Inc
NASDAQ · Healthcare · Biotechnology
Galecto Inc (GLTO) is a biotechnology company listed on NASDAQ. It is led by Lori C. Firmani, based in Ole Maaloes Vej 3, Copenhagen, Denmark, 2200, with about 5 employees. Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
Net income was -$3.1M. GLTO currently screens at market cap $1.73B.
Use this GLTO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GLTO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GLTO SEC filings page. Lician reads the product cache first so this HTML stays unique to Galecto Inc even when a live quote feed is slow.
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
GLTO Key Statistics
Market Cap
$1.73B
P/B Ratio
163.79
EPS
-$18.53
Revenue
$0.00
Net Income
-$21.44M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
5
GLTO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$21.44M | -$38.35M | -$61.62M | -$51.75M |
| EPS (Diluted) | -$18.53 | -$36.08 | -$2.43 | -$2.05 |
Total Assets
$17.13M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$14.18M
Operating Cash Flow
-$18.62M
Free Cash Flow
$0.00
Galecto Inc Company Information
- Chief Financial Officer
- Lori C. Firmani
- Headquarters
- Ole Maaloes Vej 3, Copenhagen, Denmark, 2200
- Website
- galecto.com
- Phone
- 45 70 70 52 10
- IPO / Founded
- 2020-10-29
- Sector
- Healthcare
- Industry
- Biotechnology